source
- Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.BioSpace · 4h ago↗ source
- Moderna maintains 10% growth target despite Phase 3 norovirus missModerna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUS…BioSpace · 4h ago↗ source
- BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian dataBMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…